Una Recomendación de No Hacer es una indicación de abandonar una práctica clínica de escaso valor. El escaso valor lo determina el hecho de que la práctica no reporte ningún beneficio conocido para los pacientes y/o les ponga en riesgo de sufrir daños y además pueda suponer un derroche de recursos, sanitarios y/o sociales.
Las Recomendaciones de NO Hacer incluidas en el Catálogo son las que cumplen todos estos criterios.
Para solicitar la inclusión en el Catálogo, es preciso cumplimentar el formulario.
Ver más información sobre la Iniciativa NO Hacer
National Institute Clinical Excellence (NICE) 2008.Stroke and transient ischaemic attack in over 16s. diagnosis and initial management. Clinical Guideline (CG68).
National Institute Clinical Excellence (NICE) 2014.Multiple sclerosis.Management of multiple sclerosis in primary and secondary care. Clinical Guideline (CG186).
European Commission. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. First Edition. Segna N, Patrick J, von Karsa L (eds). Luxembourg Publications Office of the European Union. 2010-LX, páginas 386.
National Institute Clinical Excellence (NICE) 2010. Alcohol-use disorders: diagnosis and management of physical complications . Clinical Guideline [CG100]
. LanzA FL, Chan FKL, Quigley EMM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104(3):728-38.
Lanas A, Hunt R. Prevention of anti-inflamatory drug-iduced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006;38:415-28
EASL Clinical Practice Guidelines on the management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417
. National Institute Clinical Excellence (NICE) 20. Coeliac disease: Recognition and assessment of coeliac disease. Clinical Guideline [NG20]
Masso Gonzalez EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflamatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010;62(6):1592-601.
Lanas A, García-Rodríguez LA, Arroyo MT, Gomollon F, Feu F, Gónzalez-Pérez A et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxigenase-2 inhibitors, tradicional non-aspirin non steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55(12):1731-8
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoartritis and rheumatoid artritis. The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000,284(10):1247-55.
McGettigan P, Henry D. Cardiovascular risk nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational Studies. PLOS Med [Internet] 2011;8(9):e1001098
Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
National Institute Clinical Excellence (NICE) 2009. Low back Pain in adults: early mamagement. Clinical Guideline [CG88]
National Institute Clinical Excellence (NICE) 2008. Osteoarthritis: the care and management of osteoarthritis in adults. Clinical Guideline [CG59]